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Background: The antitumor activity induced by intratumoral vaccination with poxvirus expressing a tumor antigen
was shown to be superior to that induced by subcutaneous vaccination. Salivary gland carcinomas overexpress
ErbB2. Trastuzumab, a monoclonal antibody to ErbB2, was proposed for salivary gland tumors treatment. We
explored the effectiveness of intratumoral vaccination with the recombinant vaccinia virus ErbB2/Neu (rV-neuT)
vaccine in hampering the growth of transplanted Neu-overexpressing BALB-neuT salivary gland cancer cells (SALTO)
in BALB-neuT mice.
Methods: BALB-neuT male mice were subcutaneously injected with SALTO tumor cells and intratumorally
vaccinated twice with different doses of either rV-neuT or V-wt (wild-type). Tumors were measured weekly. The
presence of anti-ErbB2/Neu antibodies was assayed by ELISA, immunoprecipitation or indirect immunofluorescence.
Biological activity of immune sera was investigated by analyzing antibody-dependent cellular cytotoxicity (ADCC),
SALTO cells proliferation and apoptosis, ErbB2/Neu receptor down regulation and ERK1/2 phosphorylation. Anti-Neu T
cell immunity was investigated by determining the release of IL-2 and IFN-gamma in T cells supernatant. Survival curves
were determined using the Kaplan-Meier method and compared using the log-rank test. Differences in tumor volumes,
number of apoptotic cells, titer of the serum, percentage of ADCC were evaluated through a two-tailed Student’s t-test.
Results: rV-neuT intratumoral vaccination was able to inhibit the growth of SALTO cancer cells in a dose-dependent
manner. The anti-Neu serum titer paralleled in vivo antitumor activity of rV-neuT vaccinated mice. rV-neuT immune
serum was able to mediate ADCC, inhibition of SALTO cells proliferation, down regulation of the ErbB2/Neu receptor,
inhibition of ERK1/2 phosphorylation and induction of apoptosis, thus suggesting potential mechanisms of in vivo
tumor growth interference. In addition, spleen T cells of rV-neuT vaccinated mice released IFN-gamma and IL-2 upon
in vitro stimulation with several Neu-specific peptides located in the extracellular domain of Neu sequence.
Conclusions: rV-neuT intratumoral vaccination could be employed to induce an efficient antitumor response and reject
transplanted salivary gland tumors. Our findings may have important implications for the design of cancer vaccine
protocols for the treatment of salivary gland tumors and other accessible tumors using intratumoral injection of
recombinant vaccinia virus.
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The hallmark of poxviruses utilization in anti-cancer im-
munotherapy is their ability to express large foreign genes
without significant disruption of the viral genome. This fea-
ture offers the possibility of expressing complex eukaryotic
sequences or multiple genes in permissive mammalian
cells, ensuring correct post-translational modifications [1].
To date, different poxviridae genera have been successfully
used as tumor associated antigens vectors in experimental
models. Engineered attenuated recombinant vaccinia virus
has now been widely employed as a cancer vaccine in a
large number of clinical trials as well. The results of
these trials demonstrated that recombinant vaccinia virus
infection upon vaccination was safe and that a specific
humoral or T cell response against the foreign inserted
tumor-associated antigen could be induced in several can-
cer patients [2-13]. Vaccination with recombinant vaccinia
virus can be achieved by systemic (subcutaneous, intrader-
mal, or intramuscular) or intratumoral injection [2,4-18].
Recently, it was demonstrated that the antitumor activity
induced by intratumoral vaccination with an avipox virus
expressing carcinoembryonic antigen (CEA) and multiple
co-stimulatory molecules was superior to that induced by
subcutaneous vaccination in CEA-transgenic mice [19].
Similarly, we reported that the intramammary gland vaccin-
ation with the recombinant vaccinia virus neu (rV-neuT)
vaccine was more effective than the subcutaneous vaccin-
ation in inhibiting mammary carcinogenesis in BALB-neuT
mice [20]. In addition, the intramammary delivery was
more effective than the subcutaneous vaccination in elicit-
ing anti-Neu antibodies, increasing anti-Neu IgG2a/G3
isotypes and inducing antibodies able to trigger mammary
tumor cells apoptosis and antibody-dependent cellular
cytotoxicity [20]. A prerequisite to using intratumoral de-
livery is the easy access for antigen delivery to the tumor
site. Salivary gland tumors as well as head and neck tu-
mors including tongue, floor of the mouth, palate and
mandibular mucosa and so on, appear suitable for such
vaccine delivery. Salivary gland tumors are a group of het-
erogeneous lesions which express ErbB2, whose current
treatment involves surgery and adjuvant radio(chemo)
therapy. However, therapy response rates have been gener-
ally poor for these tumors [21]. Recently, given that the
high histopatological similarity between salivary ductal
and breast carcinomas, Trastuzumab, a humanized mono-
clonal antibody to ErbB2, has been proposed as a potential
therapy for salivary gland tumors treatment. However, ac-
tive immunization targeting ErbB2 might induce tumor
growth inhibition more efficiently than passive immuno-
therapy based on the generation of an extended memory
immune response.
In this study we examined the effectiveness of the rV-
neuT intratumoral vaccination in hampering the growth
of transplanted Neu-overexpressing BALB-neuT salivarygland cancer cells (H-2d) (SALTO) in BALB-neuT mice. In
addition, we explored whether the efficiency of vaccination
was dependent on the dose of the rV-neuT vaccine (108 vs
107 vs 106 pfu). Considering previous demonstration that a
potent anti-Neu humoral response is required to prevent
mammary tumor growth in BALB-neuT vaccinated mice,
we investigated the anti-Neu humoral response following
rV-neuTvaccination as well as the in vitro biological activity
of immune sera from rV-neuT vaccinated mice. Finally, we
determined whether rV-neuT vaccination elicits anti-Neu T
cell immunity.
Our research suggests that intratumoral vaccination
using recombinant vaccinia virus could be efficiently
employed for the treatment of salivary gland tumors and
other accessible tumors.
Methods
Antibodies, peptides, reagents and cells
Neu-overexpressing salivary gland cancer cells (H-2d)
(SALTO) were kindly provided by Prof. Federica Cavallo
(University of Turin) and maintained in DMEM containing
20% fetal bovine serum (FBS). SALTO cells were estab-
lished from salivary carcinoma arising in BALB-neuT trans-
genic male mice hemizygous for p53172R-H transgene driven
by the whey acidic protein promoter [22,23]. NIH3T3 cells
expressing normal rat Neu (LTR-Neu) have been previously
characterized and kindly provided by Dr. Eddi Di Marco
(Tumor Institute of Genova) [24]. Renal epithelial cell lines
BSC-1 and NIH3T3 cells were purchased by ATCC. BSC-1,
LTR-Neu and NIH3T3 were maintained in DMEM con-
taining 10% FBS. Monoclonal antibody anti-Neu Ab4
(PC04) was purchased from Oncogene Science (Cambridge,
MA, USA). Rabbit polyclonal anti-Neu antibody (C18),
anti-ERK1/2 antibody and monoclonal antibody anti
pERK1/2 were purchased by Santa Cruz Biotechnology
(Dallas, Texas, USA). Rabbit polyclonal antibody recogniz-
ing the activated cleaved caspase-3 was purchased from
Cell Signaling Technology (Beverly, MA, USA).
Goat anti-mouse IgG Alexa fluor-488-conjugated anti-
body and goat anti-rabbit IgG Alexa fluor-594-conjugated
antibody were purchased from Life Technologies™ Molecu-
lar Probes (Oregon, USA). Protein G-sepharose, sulforho-
damine B, Concanavalin A, goat anti-rabbit secondary
antibody HRP-conjugated and all the chemicals were pur-
chased by Sigma Aldrich (Milan, IT). Synthetic peptides lo-
cated in the extracellular (Neu 15.3, aa 66–74; Neu 42, aa
169–183; Neu 98, aa 393–407; Neu 141, aa 566–580; Neu
156, aa 626–640), transmembrane (Neu 166, aa 666–680)
domains of rat Neu sequence [NCI, PubMed Accession
1202344A] [25] were previously described [26].
Poxviruses
The recombinant vaccinia virus encoding the neu onco-
gene was designated rV-neuT (vT67RR-1-1, original lot
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the full-length activated rat neu oncogene [NCI, PubMed
Accession 1202344A] [25]. The wild-type control vac-
cinia virus was designated V-wt (original lot from Therion
Biologics Corp: #062797-NYCBH). Therion Biologics Corp.
(Cambridge, MA, USA) kindly provided the poxviruses [20].
Expression of recombinant NeuT encoded by rV-neuT
was detected by Western blotting after infection of BSC-1
or NIH3T3 cells with V-wt or rV-neuT. Cells were in-
fected with 10 pfu (plaque forming unit)/cell of poxviruses
and cultured at 37°C for 18 h. Cell lysates, protein concen-
trations and immunoblotting were performed as previ-
ously described [27]. Polyclonal anti-ErbB2/Neu antibody
was used to detect recombinant NeuT.
Transgenic BALB-neuT mouse colony
Transgenic BALB-neuT male mice were routinely mated
with BALB/c females (H-2d; Charles River, Calco, Italy) in
the animal facilities of Tor Vergata University. Progenies
were confirmed for presence of the transgene by Polymer-
ase Chain Reaction (PCR) [28]. Mice were bred under
pathogen-free conditions and handled in compliance with
European Union and institutional standards for animal
research.
Recombinant vaccinia neu vaccination protocol
The protocol of vaccination was approved by the Ethical
Committee of the University of Rome “Tor Vergata” and
submitted to the Italian Health Department.
Six to 8 weeks old BALB-neuT male mice were subcuta-
neously injected in the right flank with 0.2 ml suspension
containing 1x106 SALTO cells in phosphate-buffered sa-
line (PBS). When mice presented a palpable tumor mass
around 300 mm3 (mean tumor volume 281–356 mm3),
were intratumorally vaccinated with either rV-neuT or V-
wt and boosted two weeks later.
Viruses were diluted in PBS such that the dose was
delivered in 100 μl. Mice were immunized twice. BALB-
neuT received for each vaccination a dose of 108 pfu of
either rV-neuT (n. 9 mice) or V-wt (n. 9 mice), a dose of
107 pfu of either rV-neuT (n. 8 mice) or V-wt (n. 6 mice)
and a dose of 106 pfu of either rV-neuT (n. 6 mice) or
V-wt (n. 6 mice).
Analysis of antitumor activity in vivo
Tumor growth was monitored weekly until tumor-bearing
mice were sacrificed when tumor exceeded 20 mm diam-
eter. Tumors were measured by a calliper in two dimen-
sions and the volumes were calculated using the formula:
width2 × length/2 [29].
Antibody immunity following vaccination with rV-neuT
Sera from vaccinated BALB-neuT mice were collected
prior to vaccination and 7 days after the final boost. Thepresence of antibodies reactive to p185 Neu was assayed
using NIH3T3, LTR-Neu and SALTO cells by enzyme-
linked immunosorbent assay (ELISA) or immunoprecipi-
tation following western blotting as previously described
[30-32]. For ELISA, individual rV-neuT mouse serum at
different dilutions (1:1000, 1:2500, 1:12500) was assayed
against LTR-Neu and NIH3T3 control (5×104 cells/well).
The specific absorbance of each sample was calculated by
subtracting LTR-Neu absorbance from that of NIH3T3
cells. Antibody titer was estimated as the highest immune
serum dilution generating a specific absorbance of 0.5 at
492 nm. Sera titer is the mean value of individual serum ti-
ters [33]. Individual serum samples from mice receiving
rV-neuT were randomly chosen. Individual V-wt mouse
serum was assayed at 1:250 dilution. Immunoglobulin
subclasses were determined by ELISA using a Mouse
Typer Isotyping Kit (Bio-Rad, Richmond, CA, USA) using
individual serum of rV-neuT vaccinated mice as previously
described [29,33].
For immunoprecipitation, cells were lysed in RIPA buffer
containing 1% Triton X-100, 0.5% deoxicolate, 0.1% SDS,
20 mM Tris pH 7.5, 150 mM sodium chloride, proteases
and phosphatases inhibitors. Protein concentration was de-
termined using the Bradford protein assay (Bio-Rad, Rich-
mond, CA, USA). Equal amounts of total proteins were
immunoprecipitated using sera derived from different ani-
mals immunized with rV-neuT or V-wt, and Protein G-
sepharose overnight at 4°C. The immunoprecipitates were
washed three times with RIPA buffer, boiled at 95°C and
centrifuged to remove sepharose beads. The immunopre-
cipitates were separated by SDS-PAGE and transferred into
nitrocellulose membrane [30]. After blocking with 5% non-
fat milk, the membrane was incubated with polyclonal anti-
neu antibody C18 (Santa Cruz Biotechnology Inc. Dallas,
Texas, USA). After washing, the membranes were incu-
bated with goat anti-rabbit secondary antibody HRP-
conjugated. The antigen-antibody binding was visualized by
chemiluminescence using SuperSignal West Pico Chemilu-
minescent Substrate kit (Pierce, IL, USA) [34].Biologic activity of vaccinated mouse immune sera
in vitro
Antibody-dependent cellular cytotoxicity (ADCC) was in-
vestigated as previously described [26,35]. BALB-neuT
SALTO tumor cells (5×103 cells/well) were used as targets,
while spleen cells from normal BALB/c mice were used as
effectors at 50:1. Dilutions (1:10, 1:20, 1:40) of sera pooled
from four mice vaccinated with 108 pfu rV-neuT or V-wt
were assayed. Percentage of specific lysis was calculated as
described [36]. The results represent average percentage
of cytotoxicity of two independent experiments. Four ran-
domly chosen serum samples were pooled each time and
used for two independent experiments.
Figure 1 Expression of recombinant NeuT by rV-neuT infected
BSC-1 and NIH3T3 cells. Cells were infected with 10 pfu (plaque
forming unit)/cell of poxviruses and cultured at 37°C for 18 hours.
Western blotting analysis was performed by using rabbit polyclonal
anti-Neu antibody (C18).
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immunoglobulins (Igs) from 108 rV-neuT and V-wt pooled
sera were purified by protein G and dialyzed against PBS.
Purity was determined by SDS-PAGE and Coomassie blue
staining. SALTO cells (2.5x104 cells/well) were incubated
in serum-free DMEM containing 0.2% BSA containing Igs
(20 or 10 μg/ml). Igs were replenished every 24 h. All
treatments were performed in triplicate. Survival of cells
was assessed by the Sulforhodamine B cell proliferation
assay [37]. The percent change in relative cell number was
calculated as described by Yip et al. [38].
To analyze the ability of serum antibodies to induce
down regulation of ErbB2/Neu receptor on SALTO tumor
cells, indirect immunofluorescence under native conditions
was performed. Briefly, cells were detached by incubation
with 0.02% EDTA in PBS and incubated with purified Igs
derived from rV-neuT or V-wt vaccinated mice at 4°C for
2 hours. After washes with cold PBS, cells were labelled
with goat anti-mouse IgG Alexa fluor-488-conjugated anti-
body (Life Technologies™ Molecular Probes, Oregon, USA)
for 1 hour on ice, washed and immediately observed with
an Olympus BX51 microscope; I.A.S. version 007 000 De-
convolution 2D software was used to deconvolve z series
images of stained native cells [39]. To analyze the ability
of Igs to induce receptor down regulation, SALTO tumors
cells were incubated in complete medium for 1 hour at
37°C in a CO2 incubator after immunolabeling with Igs
from rV-neuT or V-wt vaccinated mice and goat anti-
mouse-fluorescent antibody. SALTO cells were then ob-
served and analyzed as above.
For western blotting analysis of ERK1/2, 40 μg of V-wt
or rV-neuT Igs chronically treated (see above) SALTO cell
lysates were separated by SDS-PAGE and processed for
western blotting as previously described using anti-ERK1/
2 and anti-pERK1/2 specific antibodies [37,40]. The inten-
sity of the bands obtained in two independent experiments
was quantified using the ImageJ software after blot scan-
ning, and densitometric ratios between the phosphory-
lated and total levels of each protein were calculated.
For detection of programmed cell death, SALTO cells
(2.5×104 cells/well) were incubated in serum-free DMEM
containing 0.2% BSA containing Igs (10 μg/ml) from rV-
neuT or V-wt vaccinated mice for 72 hours. Igs were
replenished every 24 h. Cells were fixed in 4% formaldehyde
for 15 min and after washing they were incubated with the
polyclonal anti-activated caspase-3 antibody for 1 h. After
washing, cells were labelled with goat anti-rabbit IgG Alexa
fluor-594-conjugated antibody (Life Technologies™ Molecu-
lar Probes, Oregon, USA) for 60 min [26]. After washing,
cells were incubated with 0.1 μg/ml Hoechst 33342 and
mounted under a coverslip in glycerol. Staurosporine at
1 μM incubated for 24 h was used as positive control. The
percentage of apoptotic cells was calculated by determining
the activated caspase-3 positive cells/total cells evaluatingfive randomly chosen microscopic fields. Count of apop-
totic cells was done in a blinded fashion.
IL-2 and IFN-γ release assay
Spleen cells from BALB-neuT vaccinated mice were har-
vested 7 days after the final vaccination as previously
described [26]. Spleen mononuclear cells (2×106/well in
24-well plates) were incubated with Concanavalin A
(ConA, 2 μg/ml), several Neu peptides (10 μg/ml) or a
control gag peptide. Neu peptides were selected based
on immunoreactivity in vitro with lymphocytes from
BALB-neuT mice vaccinated with recombinant adeno-
virus, LTR-Neu and rV-neuT [20,26,41]. IL-2 and IFN-γ
release into the supernatant was measured using an en-
zymatic immunocapture assay (Quantikine, R&D Sys-
tems, Minneapolis, MN, USA).
Statistical analysis
Mean and standard deviation describes continuous vari-
ables. Survival curves were determined using the
Kaplan-Meier method and compared by the log-rank
test (Mantel-Cox). Differences in tumor volumes, num-
ber of apoptotic cells, titer of the serum, percentage of
ADCC, intensity of immunoreactive bands were evalu-
ated by a two-tailed Student’s t-test. Statistical associa-
tions were considered significant at p-values ≤0.05.
Results
Expression of recombinant NeuT encoded by rV-neuT
Expression of recombinant NeuT encoded by rV-neuT
was detected by Western blotting after rV-neuT infection
of BSC-1 and NIH3T3 cells. As shown in Figure 1, poly-
clonal anti-HER-2/neu antibody detected a 185 kDa
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cells but not in V-wt-infected cells.
Inhibition of tumor growth by recombinant vaccinia neu
(rV-neuT) vaccine
To determine whether the vaccination with rV-neuT was
able to induce inhibition of the growth of transplanted
p185 Neu positive tumor (SALTO) and whether it was
dependent on rV-neuT doses, BALB-neuT male mice were
challenged in the right flank with 1x106 SALTO cells, and
immunized twice intratumorally with three different doses
of rV-neuT or V-wt (108, 107, 106 pfu). Vaccinations were
performed at two weeks interval.
Vaccination with rV-neuT at the dose of 108 pfu was able
to induce regression of transplanted tumors (Figure 2), and
to elicit an immunological memory that protected mice
against a second injection of SALTO cells (data not shown).
When considering the effectiveness of the rV-neuT vaccine
independently of dose, the mean survival time of mice vac-
cinated with rV-neuT versus those receiving the V-wt was
14.8 versus 2.63 weeks (p < 0.0001) (Figure 2, Panel B).
The 108 pfu dose vaccination was started when mean
tumor volume was 307 mm3 (9 mice) and 321 mm3 (9
mice) in rV-neuT or V-wt vaccinated-mice, respectively.
Two weeks after the first vaccination mean tumor volume
of V-wt vaccinated mice reached 3351 mm3 while mean
tumor volume of rV-neuT vaccinated mice was 123 mm3
(p < 0.001) (Figure 2, Panel A). At this stage 1/9 rV-neuT
vaccinated mice was tumor free. One mouse of this groupFigure 2 Inhibition of transplantable salivary gland (SALTO) tumor ce
tumor volume between V-wt and rV-neuT vaccinated BALB-neuT mice after
Differences in mean survival time of rV-neuT- and V-wt-vaccinated mice ind
survival between V-wt and rV-neuT vaccinated BALB-neuT mice after differe
vaccinated mice are reported in “Materials and methods”.died for unknown reason although the tumor volume was
diminishing after the first vaccination. Four weeks after the
first vaccination 5/9 rV-neuT vaccinated mice were tumor
free and two weeks later 8/9 rV-neuT vaccinated mice were
tumor free and remained in this status until the 30th week.
Conversely, all V-wt vaccinated mice were sacrificed for
exceeded tumor volume or spontaneously died at the third
week after the first vaccination (p < 0.001) (Figure 2, Panel
C). Overall, the mean survival time of mice vaccinated with
108 pfu rV-neuTversus those receiving the 108 pfuV-wt dose
was 27 versus 2.25 weeks (p < 0.0001) (Figure 2, Panel C).
The 107 pfu dose vaccination was started when mean
tumor volume was 356 mm3 (8 mice) and 332 mm3 (6
mice) for rV-neuT and V-wt vaccinated mice, respect-
ively. Three weeks after the first vaccination mean tu-
mors volume was 1052 mm3 and 4319 mm3 in rV-neuT e
V-wt vaccinated mice, respectively (p < 0.001) (Figure 2,
Panel A). Four mice vaccinated with rV-neuT were sacri-
ficed four weeks after the first vaccination for exceeded
tumor size and one mouse died, while all V-wt vaccinated
mice were sacrificed within the fourth week after the first
vaccination (p < 0.001). Only 2/8 mice of the rV-neuT vac-
cinated group were still alive at the 7th week but they were
sacrificed within the 8th week (Figure 2, Panel C). The
mean survival time of mice vaccinated with 107 pfu rV-
neuT versus those receiving the 107 pfu V-wt dose was
5.25 versus 3 weeks (p = 0.0003) (Figure 2, Panel C).
Finally, the 106 pfu dose vaccination was started when
mean tumor volume was 281 mm3 (6 mice) and 298 mm3lls growth in vivo by rV-neuT vaccination. Panel A: Differences in
different doses of vaccination (108 pfu, 107 pfu and 106 pfu). Panel B:
ependently of the dose of vaccination. Panel C: Differences in mean
nt doses of vaccination (108 pfu, 107 pfu and 106 pfu). Numbers of
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after the first vaccination mean tumor volume was
624 mm3 and 2167 mm3 in the group of mice vaccinated
with rV-neuT and V-wt, respectively (p = 0.0096) (Figure 2,
Panel A). Two out of six mice vaccinated with V-wt were
sacrificed at this stage. At the third week after vaccination
3/6 V-wt vaccinated mice were sacrificed while 1/6 rV-
neuT vaccinated mice was tumor free (mean tumor vol-
ume: 3385 vs 699 mm3 for the vaccination with V-wt and
rV-neuT, respectively; p = 0.0009). Only 1/6 mice of the
group vaccinated with V-wt was alive four weeks after the
first vaccination. Conversely 6/6 rV-neuT vaccinated mice
(mean tumor size: 901 mm3) were alive at this stage. At
the 7th week, only 1/6 rV-neuT vaccinated mice was alive
and remained tumor free until the 30th week (Figure 2,
Panel C). The mean survival time of mice vaccinated with
106 pfu rV-neuT versus those receiving the 106 pfu V-wt
dose was 9.33 versus 2.83 weeks (p = 0.0006) (Figure 2,
Panel C).
Overall, when comparing the survival of BALB-neuT
mice upon vaccination it was observed that the risk of
growth of SALTO tumor cells in the rV-neuT vaccinated
group was 0.04 in comparison to V-wt vaccinated group. In
addition, the dose of the vaccine significantly affected mice
survival (Table 1). The risk of developing tumors in the 106
pfu and 107 pfu rV-neuT vaccinated groups was 10.26 and
14.05 in comparison to the 108 pfu rV-neuT vaccinated
group (Table 1). No difference was found between the 107
and 106 pfu rV-neuT vaccination.
These results suggest that rV-neuT intratumoral vaccin-
ation is able to induce inhibition of the growth of trans-
planted salivary gland Neu positive tumor cells and that the
effect of vaccination is dose-dependent. The lower doses
(106 e and 107 pfu) were able to induce in rV-neuT vacci-
nated mice only a delay in SALTO tumor cells growth as
compared to V-wt vaccinated mice. In this regard, the
mean survival time of mice vaccinated with 108 pfu rV-
neuT versus those receiving the 107 pfu rV-neuT and 106
pfu rV-neuT doses was 27 versus 5.25 weeks (p = 0.0007)
and 9.33 (p = 0.012) weeks, respectively (Figure 2, Panel C).Table 1 Comparison of BALB-neuT mice survival after rV-neuT
Variable Contrast Hazard ratio
Vaccine rV-neuT vs V-wt 0.04
rV-neuT 108 pfu vs V-wt 108 pfu 0.035
rV-neuT 107 pfu vs V-wt 107 pfu 0.022
rV-neuT 106 pfu vs V-wt 106 pfu 0.04
Dose rV-neuT 107 pfu vs rV-neuT 108 pfu 14.05
rV-neuT 106 pfu vs rV-neuT 108 pfu 10.26
rV-neuT 106 pfu vs rV-neuT 107 pfu
NS: not significant.Anti-Neu humoral response following rV-neuT vaccination
Previous studies reported that anti-Neu humoral response
is required to inhibit mammary tumor growth in BALB-
neuT vaccinated mice [35]. Antibody response to p185
Neu was quantitatively and qualitatively evaluated by im-
munoprecipitation following western blotting, ELISA and
immunofluorescence in order to determine whether differ-
ences in humoral response existed between rV-neuT or V-
wt administration before and after vaccination.
Specific anti-Neu reactivity in sera from rV-neuT vacci-
nated mice was visualized by immunoprecipitation followed
by western blotting by using an anti-Neu specific antibody,
and LTR-Neu and SALTO cells as antigen source.
The expression of p185 Neu in LTR-Neu and in
SALTO cells was analyzed by western blotting. As shown
in Figure 3, Panel A, NIH3T3 fibroblasts did not express
p185 Neu, while LTR-Neu and SALTO cells showed high
levels of expression of p185 Neu. Specific antibody response
to Neu was qualitatively evaluated by indirect immuno-
fluorescence and immunoprecipitation analysis. Mouse
pre-immune or immune sera were collected prior to vac-
cination or one week after the final boost. SALTO cells
were incubated with purified Igs derived from rV-neuT or
V-wt BALB-neuT vaccinated mice followed by labeling with
goat anti-mouse IgG Alexa fluor-488-conjugated antibody.
Figure 3, Panel B shows representative membrane staining
of SALTO cells by Igs form rV-neuT vaccinated mice simi-
larly to that of monoclonal anti-Neu antibody Ab4. Con-
versely, Igs derived from V-wt vaccinated Balb-neuT mice
or pre immune serum (data not shown) did not bind
SALTO cells. Sera were employed to immunoprecipitate
p185 Neu from LTR-Neu or SALTO cells. Specific reactiv-
ity was visualized by immunoblotting of immunoprecipi-
tates using a Neu-specific commercial antibody (C18).
Analysis of serum reactivity taken from representative
108 pfu rV-neuT and V-wt vaccinated mice is depicted
in Figure 3, Panel C. rV-neuT vaccination was able to in-
duce specific anti-Neu antibodies able to immunoprecipi-
tate the antigen from LTR-Neu and SALTO cells. Specific
antibodies were detected in all rV-neuT vaccinated mice.and V-wt vaccination by log-rank (Mantel-Cox) test
95% hazard ratio confidence limits p value
Lower Upper
0.014 0.11 < 0.0001
0.007 0.19 < 0.0001
0.003 0.18 0.0003
0.006 0.25 0.0006
3.05 64.66 0.0007
1.65 63.63 0.012
NS
Figure 3 Anti-Neu humoral response following rV-neuT vaccination. Panel A: p185 Neu expression in NIH3T3 cells encoding normal rat Neu
(LTR-Neu) and in Neu-overexpressing BALB-neuT salivary gland cancer (SALTO) cells by western blotting. A specific polyclonal anti-Neu (C18)
antibody was used. NIH3T3 cells were used as negative control. Panel B: Igs from rV-neuT vaccinated mice recognize p185 Neu expressed on the
surface of SALTO tumor cells. Immunofluorescence was performed using purified Igs (1μg/ml) of BALB-neuT mice vaccinated with rV-neuT or
V-wt. The specific monoclonal antibody anti-Neu Ab4 was used as positive control. Olympus BX51 microscope and I.A.S. version 007 000
Deconvolution 2D software were used to deconvolve z series images of stained native cells. Original magnification x400. Panel C: Serum antibody
response of mice upon vaccination with rV-neuT. Numbering identifies immune sera of individual mice. Mouse pre-immune or immune sera were
collected prior to vaccination or one week after the second immunization and employed in immunoprecipitation of Neu from LTR-Neu or SALTO
tumor cells. p185 Neu specificity was visualized by immunoblotting analysis using receptor-specific polyclonal antibody of immunoprecipitates
and compared to direct immunoblotting of LTR-Neu lysate as positive control, or NIH3T3 as negative control.
Table 2 Immunoreactivity of rV-neuT vaccinated
BALB-neuT mouse sera with Neu
Dose of
rV-neuT
Number of mice
with immune
response/totala
Number of
pooled sera
Serum
titer (SD)b
108 pfu 8/8 5 11875c (1250) p = 0.000288d
p = 0.0045e
107 pfu 4/4 4 1950 (1706)
106 pfu 6/6 5 3380 (3750)
aImmune response was determined by ELISA against LTR-Neu and NIH3T3.
Optical density (O.D) of V-wt sera at 1:250 to LTR-Neu was ≤0.3. These values
were considered negative. Values for rV-neuT serum was considered positive
when specific O.D value was ≥0.5 at the 1:1000 dilution.
bImmune sera titers of BALB-neuT vaccinated mice were determined by ELISA
against LTR-Neu and NIH3T3 using individual serum at different dilutions
(1:1000, 1:2500, 1:12500). Sera titer represents the mean value of individual
serum titer ± standard deviation (SD).
cTiter was estimated as the highest immune serum dilution generating a
specific absorbance of 0.5 at 492 nm.
d108 pfu vs 107 pfu.
e108 pfu vs 106 pfu.
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able to immunoprecipitate the antigen from LTR-Neu.
Specific antibody response to Neu was quantitatively
evaluated by ELISA. As shown in Table 2, 108 pfu rV-neuT
vaccinated mice developed a significantly higher titer of
anti-Neu antibodies than 107 pfu rV-neuT and 106 pfu rV-
neuT vaccinated mice. No significant difference on anti-
Neu titer antibodies was observed between the 107 pfu
rV-neuT and 106 pfu rV-neuT dose. It is of note that anti-
Neu serum titer paralleled antitumor in vivo activity of
rV-neuT vaccinated mice. The administration of V-wt did
not result in the induction of anti-Neu antibodies.
Experiments were then carried out to evaluate the iso-
type of the immunoglobulins (Igs) elicited by rV-neuT vac-
cination. As shown in Table 3, anti-Neu-immunoglobulins
of rV-neuT vaccinated Balb-neuT mice were mainly of the
IgG1 (32%), IgG2a (22%) and IgG2b (16%) isotype with a
lesser amount of IgG3, IgM and IgA.
Table 3 Anti-neu-immunoglobulins isotype of rV-neuT vaccinated BALB-neuT mice
Immunoglubulins isotype against Neu
IgG1 IgG2a IgG2b IgG3 IgM IgA
32.52 ± 7.37a 22.28 ± 5.43 16.65 ± 5.54 11.5 ± 1.9 11.15 ± 1.78 5.87 ± 0.8
aResults are the mean of the percent (±standard deviation) of each immunoglobulins isotype relative to the total sera immunoglobulin content
(at 1:1500) of 108 pfu rV-neuT vaccinated mice.
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vaccinated mice
ADCC, cell proliferation of BALB-neuT SALTO tumor
cells, receptor down regulation and induction of apoptosis
in SALTO cells were analyzed using pooled sera or purified
Igs from108 pfu rV-neuT or V-wt vaccinated mice in order
to investigate potential mechanisms of tumor inhibition by
anti-Neu Igs. As shown in Figure 4, Panel A, spleen cells
produced no cytotoxicity in the presence of pooled seraFigure 4 In vitro biological activity of immune sera or purified immun
by sera from 108 pfu rV-neuT vaccinated mice. SALTO tumor cells were exposed
mononuclear effector cells derived from normal BALB/c spleens at a ratio of 50:
experiments. *p ≤ 0.01. Panel B: Effects of anti-Neu Igs on SALTO cell proliferatio
medium containing 0.2% BSA with or without rV-neuT or V-wt purified Igs. Relat
of 72 h at 37˚C using a sulforhodamine B based proliferation assay and express
0.2% BSA). *p ≤ 0.01. Panel C: p185 Neu receptor down regulation by anti-Neu I
with goat anti-mouse IgG Alexa fluor-488-conjugated antibody. Original magnif
rV-neuT Igs chronically treatment of SALTO tumor cells. Serum depleted SALTO
and ERK2 and pERK1/pERK2 expression was analyzed by western blotting. Dens
protein are reported. Panel D: Effects of anti-Neu Igs on SALTO cells apoptosis. S
containing 0.2% BSA with or without rV-neuT or V-wt purified Igs (10 μg/ml) and
(1 μM) treatment was used as positive control. Nuclei were counterstained withfrom 108 pfu V-wt vaccinated mice. Conversely, spleen cells
in the presence of pooled sera from 108 pfu rV-neuT vacci-
nated mice mediated higher ADCC (p≤0.01) at 1:10 and
1:20 dilution (38.5 and 38.25%, respectively) than sera from
V-wt vaccinated mice (3 and 0.75%, respectively).
To determine whether specific anti-Neu Igs were able to
interfere with in vitro cell growth, SALTO cells were chron-
ically treated (72 hours) with different concentrations of
purified Igs from rV-neuT or V-wt vaccinated mice inoglobulins from rV-neuT vaccinated mice. Panel A: ADCC elicited
for 2 hours to sera pooled from rV-neuT or V-wt vaccinated mice and with
1. Results represent average percent cytotoxicity of two independent
n. SALTO tumor cells following serum depletion were incubated in DMEM
ive cell numbers of triplicate experiments were determined after incubation
ed as percent increase or decrease in comparison to vehicle control (DMEM
gs. SALTO cells were stained with stained with rV-neuT purified Igs and then
ication x 500. Expression and phosphorylation of ERK1 and ERK2 after
cells were treated with rV-neuT- and V-wt Igs and the ratio between ERK1
itometric ratios between the phosphorylated and total levels of each
ALTO cells were plated at 2.5×104 cells/well, incubated in DMEM medium
stained with a specific anti-cleaved caspase 3 antibody. Staurosporine
Hoechst 33342. Original magnification x400.
Table 4 T cell immune response of BALB-neuT mice
following vaccination with rV-neuT
T cell in vitro
stimulus
Neu peptide
sequence
IL-2 release* IFN-γ
rV-neuT V-wt rV-neuT V-wt
r15.3 TYVPANASL 208 44 519 ≤18
r41 DMVLWKDVFRKNNQL 359 43 475 ≤18
r98 IAPLRPEQLQVFETL 343 44 510 ≤18
r141 LPCHPECQPQNSSET 209 43 555 ≤18
r156 GICQPCPINCTHSCV 265 45 365 ≤18
r166 VLLFLILVVVVGILI 239 42 585 ≤18
GAG 35 41 3 ≤18
ConA 1450 2800 2890 3150
*Spleen cells from vaccinated mice were stimulated in vitro with Neu-specific
peptides. IL-2 and IFN-γ was quantitated in the supernatant (pg/ml) as a measure
of T cell immunoreactivity with specific Neu epitopes. ConcanavalinA (ConA) for
global T cell activation and an unrelated gag peptide served as positive and
negative control, respectively.
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B, specific inhibition of cell growth was observed after treat-
ment with Igs from rV-neuT vaccinated mice both at a con-
centration of 20 and 10 μg/ml (50.5 and 42.5% respectively,
p ≤ 0.01). Treatment with V-wt vaccinated mice Igs was not
effective on cell proliferation.
Trastuzumab, a monoclonal antibodies to p185, was
shown to induce down regulation of p185 receptor on
cell membrane, to block its function by hampering the
formation of homodimers and heterodimers and ligand
binding [42]. The ability of purified Igs from vaccinated
mice to induce down regulation of p185 Neu was inves-
tigated by immunofluorescence and deconvolution ana-
lysis of immunolabeled SALTO cells. SALTO cells were
stained with rV-neuT purified Igs, then with a goat anti-
mouse fluorescent antibody and incubated for 1 hour at
37°C in a CO2 incubator in complete medium. As shown
in Figure 4, Panel C, Igs from rV-neuT vaccinated mice
were able to induce down regulation of the p185 Neu re-
ceptor expressed on the cell surface of SALTO cells.
MAP (Mitogen Activated Protein) kinases, ERK1 and
ERK2, are activated by ErbB2/Neu receptor and trans-
duce proliferation signals. Given that chronic treatment
with 108 pfu rV-neuT Igs was able to specifically inhibit
SALTO cell growth, we investigated whether phosphor-
ylation of ERK1/ERK2 in SALTO cells was affected by
rV-neuT Igs treatment (10 μg/ml). V-wt purified Igs
were used as control. The amount of phosphorylated
ERK1 and ERK2 (pERK1 and pERK2) proteins were
compared to total ERK proteins. The level of total
ERK1/2 did not change after 108 pfu rV-neuT or V-wt
purified Igs treatment. Conversely, phosphorylation of
ERK1 was significantly inhibited by 108 pfu rV-neuT
Igs as compared to V-wt Igs treatment (ratio 1.85 vs
2.80, p = 0.011). pERK2 was only slightly inhibited (ra-
tio 0.50 vs 0.63, p = 0.028).
To determine whether anti-Neu Igs were able to trig-
ger apoptosis, SALTO cells were labeled with anti-
activated caspase-3 polyclonal antibody after rV-neuT
or V-wt Igs (10 μg/ml) chronic treatment. Figure 4,
Panel D shows detection of cleaved caspase-3 in SALTO
cells. The fraction of apoptotic cells was determined
relative to cleaved caspase-3 positive cells. rV-neuT
purified Igs induced apoptosis in 19.2% (p < 0.001) of
SALTO cells. In comparison, treatment with V-wt Igs
triggered irrelevant SALTO cells apoptosis (0.2%).
Treatment of cells with 1 μg/ml staurosporine resulted
in 60% apoptotic cells.
Overall, our results indicate that in vitro biological activ-
ity (ADCC, inhibition of cell proliferation, down regulation
of p185 Neu receptor, inhibition of ERK1/2 phosphoryl-
ation and induction of apoptosis) of rV-neuT immune sera
can provide the ability of rV-neuT vaccinated mice of inter-
fering with tumor growth in vivo.T cell immune response induced by rV-neuT vaccination
Splenocytes isolated from mice vaccinated with rV-neuT
or V-wt after the final boost, were examined for their abil-
ity to proliferate under various Neu peptides. Release of
IL-2 and IFN-γ was measured in the supernatant to assess
T cell immunoreactivity with specific Neu epitopes. Re-
sults are reported in Table 4. All analyzed Neu peptides,
except for an unrelated gag peptide, were able to specific-
ally activate splenocytes from rV-neuT immunized BALB-
neuT mice. ConA was used as positive control.
However, the extent of IL-2 and IFN-γ release was
dependent on the stimulating Neu peptide. The strongest
IL-2 release was observed upon stimulation with r41 and
r98 peptides which are located in the extracellular domain
of rat Neu sequence. Lower IL-2 release was observed upon
stimulation with r166 and r156 peptides located in the
transmembrane and extracellular domains, respectively, or
with r15.3 and r141 peptides. These latter are located in the
extracellular domain. The strongest IFN-γ release was de-
tected upon stimulation with r166 and r141 peptides. High
levels of IFN-γ were also obtained upon r15.3 and r98 pep-
tides. The r41 peptide, which stimulated the higher IL-2 re-
lease, induced less IFN-γ release. Within the different
peptides, r156 stimulated the lowest IFN-γ release.
Discussion
The incidence of head and neck carcinomas (HNC) is in-
creasing worldwide and despite advances in their treat-
ment, the survival rate of patients with this type of cancer
has not substantially changed over the last two decades
[43]. Salivary gland carcinomas are head and neck tumors
of heterogeneous morphology that require typical surgical
and adjuvant therapy [44]. Conservative surgery with
nerve monitoring remains the state-of-the-art. Adjuvant
radio(chemo)therapy is shown to increase local tumor
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[44]. Thus, the development of novel therapies can supple-
ment the pharmaceutical armamentarium presently used
for the treatment of HNC and salivary gland carcinomas.
A significant tumor specific overexpression of all four
ErbB receptors including EGFR, ErbB2, ErbB3, and ErbB4
has been reported in head and neck squamous cell carcin-
omas (HNSCC) [45,46]. ErbB2 overexpression was ob-
served in about 20% of patients with salivary duct cancer
(SDC) [47], a rare high-grade aggressive tumor subtype of
salivary gland carcinoma. In agreement with both EGFR
and ErbB2 overexpression, cetuximab and trastuzumab,
which target EGFR and ErbB2, respectively, represent im-
portant tools for treatment of salivary gland carcinomas
[48]. Indeed, it was reported that a patient with SDC posi-
tive for ErbB2 had a complete objective response after
combined treatment with paclitaxel, carboplatin, and tras-
tuzumab [49]. Similarly, it was described a case of ErbB2-
positive metastatic submandibular SDC with a complete
and durable clinical response after treatment with trastu-
zumab in combination with chemotherapy [50]. In
addition, resolution of measurable and minimal residual
disease in a patient with salivary duct cancer treated with
trastuzumab, lapatinib, and bevacizumab, with treatment
ongoing for more than 2 years was observed [51]. Thirteen
patients with SDC and ErbB2 expression were treated with
trastuzumab in adjuvant (n = 8) or palliative (n = 5) setting.
It was reported that all patients with metastatic disease (5/
5 patients) responded to treatment with trastuzumab. One
patient achieved a complete response and remains with no
evidence of disease 52 months after initiation of trastuzu-
mab. The median duration of response was 18 months
[52]. However, it was also reported in breast cancer pa-
tients that the objective response to trastuzumab mono-
therapy had a median duration of 9 months, and that the
majority of responsive patients displayed resistance within
1 year [53]. Conversely, combination therapy with trastu-
zumab and an ErbB2/Neu T helper peptide vaccine was
well tolerated and it was associated with minimal toxicity
in patients with metastatic breast cancer. In addition,
the combinatorial approach of the vaccine with passive
immunotherapy resulted in prolonged, robust, antigen-
specific immune responses in treated patients and induced
epitope spreading [54]. In agreement with these evidences
it is reasonable to investigate ErbB2 cancer vaccine ap-
proaches with the aim to improve the objective tumor in-
hibitory response in salivary gland carcinomas.
Poxvirus represents an attractive delivery vehicle of
tumor antigens due to the normal post-translational modi-
fication of the inserted antigen and strong immunogenicity
[2,3,5]. Engineered attenuated recombinant vaccinia virus
encoding for tumor associated antigens has now been
widely employed as a cancer vaccine in several clinical trials
[4-9,11,13,16,18,55]. Vaccination with recombinant vacciniavirus can be achieved by systemic or local intratumoral (i.t.)
injection [2,4-9,11,13,16,18].
Recently, it was demonstrated that the antitumor activ-
ity induced by i.t. vaccination with an avipox virus ex-
pressing carcinoembryonic antigen (CEA) and multiple
co-stimulatory molecules was superior to that induced by
systemic (subcutaneous) vaccination in CEA-transgenic
mice [19]. Similarly, we recently demonstrated that local
delivery of recombinant vaccinia virus encoding for neu
(rV-neuT) was superior to systemic vaccination in inhibit-
ing the neu oncogene-mediated mammary carcinogenesis
[20]. Besides, i.t. injection of recombinant attenuated
Salmonella enterica serovar Typhimurium vaccine has
been reported to significantly inhibit Her-2/neu-express-
ing tumor growth. The vaccine elicited transformation of
immunosuppressive myeloid-derived suppressor cells into
TNF-α-secreting neutrophils and reduced the generation
of Treg cells [56]. Similarly, i.t adenovirus (Ad) vaccination
supported the generation of both Neu- and Ad-specific T
effector cells [57]. Of note, it was reported that i.t. vaccin-
ation with vaccinia-expressing the tumor antigen HY and
granulocyte macrophage colony-stimulating factor was
able to overcome immunological ignorance to the tumor
antigen [58]. Head and neck cancers are loco-regional dis-
eases that appear at or close to the body surface and are
easily accessible. Thus, the accessibility of salivary gland
tumors allow one to envision intratumoral immunother-
apy in a neoadjuvant setting.
The attempt to use intratumoral vaccination in HNC
was reported by Dasgupta et al. [59]. In this study it was
demonstrated that recombinant vaccinia virus expressing
interleukin-2 invoked anti-tumor cellular immunity in an
orthotopic murine model of HNC. However, no antigen
was delivered by using this approach.
In this report, we investigated the efficacy of the rV-neuT
intratumoral vaccination in hampering the growth of trans-
planted Neu-overexpressing salivary gland cancer cells
(SALTO) in syngeneic, Neu-tolerant BALB-neuT mice. In
addition, we determined whether the efficiency of vaccin-
ation was dependent on rV-neuT doses (108-106 pfu). Mice
transgenic for the rat neu oncogene (BALB-neuT) are usu-
ally employed to evaluate the ability of ErbB2/Neu vaccines
to inhibit the progression of neu-driven carcinogenesis [60].
Our observations indicated that the efficiency of vaccin-
ation was dose-dependent. Mice vaccinated with 108 pfu
rV-neuT had a mean survival time of 27 weeks while those
receiving the 107 pfu and 106 pfu rV-neuT doses had a
mean survival time of 5.25 and 9.33 weeks, respectively. rV-
neuT vaccination at the dose of 108 pfu induced regression
of transplanted tumors while that at 106 e and 107 pfu pro-
voked a delay in the tumor growth as compared to V-wt
vaccination. The risk of developing tumors in the 106 pfu
and 107 pfu rV-neuT vaccinated groups was 10.26 and
14.05 in comparison to the 108 pfu rV-neuT vaccinated
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with rV-neuT, independently of the dose, was 14.8 weeks
while of those receiving the V-wt was 2.63 weeks. It is of
note that 8/9 rV-neuT vaccinated mice were tumor free six
weeks after the first vaccination and remained in this status
until the 30th week. Conversely, V-wt vaccinated mice were
sacrificed for exceeded tumor volume or spontaneously
died at the third week after the first vaccination.
We previously established that immune response and
antitumor activity were increased by repeated rV-neuT
vaccinations. Accordingly, we performed two immuni-
zations. One of the potential drawbacks in the use of
many recombinant vaccinia immunizations in patients
is that pre-existing and/or stimulated antibody and T
cell response to vaccinia virus will preclude the spread
of the administered vaccinia virus and thus decrease
the expression of the inserted antigen. On the other
hand, it should be noted that smallpox was eradicated
worldwide more than 25 years ago; thus, young people
are no longer vaccinated. In addition, recombinant avi-
pox virus, which has a limited viral replication, can be
employed to boost immune response after priming with
recombinant vaccinia.
The extent of tumor growth interference in vivo was as-
sociated with high serum levels of anti-Neu antibodies,
which were able to recognize p185 Neu expressed on
SALTO tumor cells. 108 pfu rV-neuT vaccinated mice de-
veloped a significantly higher titer of anti-Neu antibodies
than 107 and 106 pfu rV-neuT vaccinated mice. Thus, the
amount of produced anti-Neu antibodies was coincident
with the efficiency of in vivo anti-tumor activity of rV-
neuT vaccinated mice.
Individual mechanisms including ADCC, CDC (com-
plement dependent cytotoxicity), induction of apoptosis,
or receptor down regulation have been implicated to
elucidate the inhibitory effect of anti-ErbB2/Neu anti-
bodies on the growth of cancer cells expressing ErbB2/
Neu [35,61-67]. In this study, we demonstrated that Igs
from rV-neuT vaccinated mice inhibited in vitro cell pro-
liferation, mediated ADCC and induced apoptosis of
SALTO tumor cells. Indeed, immune sera from rV-neuT
vaccinated mice were able to mediate ADCC in vitro.
Igs of the IgG2a isotype have been shown to mediate a
more potent ADCC than other Ig isotypes in mice [68].
Anti-Neu antibodies of the IgG2a isotype are well repre-
sented in sera of rV-neuT vaccinated mice. Purified Igs
from rV-neuT vaccinated mice were also able to induce
inhibition of SALTO tumor cell growth.
Trastuzumab was shown to induce down regulation of
p185 Neu receptor and to block receptor function [42].
We demonstrated that chronic treatment with purified
rV-neuT Igs were able to induce down regulation of
p185 Neu receptor in SALTO cells. This biological effect
can make the receptor unavailable for ligands bindingthus blocking its signal transduction as we observed by
revealing inhibition of the MAP kinases cascade upon
rV-neuT Igs incubation of SALTO cells. Moreover, rV-
neuT vaccinated mice purified Igs were able to induce
apoptosis of BALB-neuT tumor cells in vitro.
It has been demonstrated that cytokines and antibody
production are mostly responsible for inhibition of tumor
growth in BALB-neuT mice, while cytotoxic T lympho-
cytes might have a marginal role [35,69]. Here, we found
that spleen T cells of rV-neuT vaccinated mice released
IFN-γ and IL-2 upon stimulation with several Neu-
specific peptides. Recognition of these epitopes in vivo po-
tentially activates T cells to secrete IFN-γ thus determining
ischemic necrosis at the tumor site. Such immunodomi-
nant epitopes might boost an immune response in BALB-
neuT mice. Overall, our study suggests that rV-neuT i.t
vaccination could be employed to induce an efficient anti-
tumor response and reject transplanted salivary gland tu-
mors. A Phase I study of i.t vaccine administration in men
with locally recurrent or progressive prostate cancer was
performed [70]. The intraprostatic administration of PSA-
TRICOM [encoding transgenes for prostate-specific anti-
gen (PSA) and 3 costimulatory molecules] poxviral vaccine
was safe and feasible and could generate a significant im-
munologic response. Indeed, improved serum PSA kinet-
ics and intense post-vaccination inflammatory infiltrates
were seen in the majority of patients after vaccination
[70]. Local vaccination with recombinant vaccinia virus
might provide danger signals which can induce a specific
immune response by alerting and activating specialized
antigen presenting cells expressing costimulatory mole-
cules and thus promoting T and B cell activation [71].
Active immunization targeting ErbB2 might block tumor
growth more proficiently than passive immunotherapy
thanks to the activation of a persistent memory immune
response. It would also be useful in boosting a spontan-
eous occurring ErbB2 immune response. Moreover, an
ErbB2 vaccine-based therapy might be helpful to a single
anti-ErbB2 Mab therapy by concurrently inducing T and B
cell immunity to several immunodominant epitopes.
Our findings may have a significant role for planning
cancer vaccine protocols for the treatment of salivary
gland tumors and other accessible tumors using i.t injec-
tion of recombinant vaccinia virus.Conclusions
rV-neuT intratumoral vaccination could be employed to
induce an efficient antitumor response and reject trans-
planted salivary gland tumors. Our findings may have
important implications in the design of cancer vaccine
protocols for the treatment of salivary gland tumors and
other accessible tumors using intratumoral injection of
recombinant vaccinia virus.
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